QUELL
LIVE

Serial Number

88372290

Owner

Quell Therapeutics Limited

Attorney

Steven T. Shelton

Filing Date

Apr 4, 2019

Add to watchlist:

No watchlists yet
View on USPTO

QUELL Trademark

Serial Number: 88372290 • Registration: 6077717

QUELL is a trademark filed by Quell Therapeutics Limited on April 4, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Quell Therapeutics Limited (4 trademarks)

3rd Floor, Translation & Innovation Hub
London W120BZ , GB

Entity Type: 99

Trademark Details

Filing Date

April 4, 2019

Registration Date

June 16, 2020

Published for Opposition

March 31, 2020

Goods & Services

Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management

Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management

Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management

advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 16, 2025 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 25, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 25, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 25, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 25, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 25, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 25, 2023 COAR
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 31, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 31, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 25, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 25, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 25, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 25, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 25, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 13, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 13, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 13, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 23, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 23, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 23, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 30, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2019 CRFA
ASSIGNED TO LIE
Dec 30, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2019 CNRT
ASSIGNED TO EXAMINER
Jun 14, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 22, 2019 NWOS
NEW APPLICATION ENTERED
Apr 8, 2019 NWAP